Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7331788 | 0.80 | CA2 (0.33) | CA2CA4CA5AUSP2TSHR | |
| SCHEMBL7334090 | 0.80 | ALDH1A1 (0.38) | CA2CA4CA5AUSP2TSHR | |
| SCHEMBL7322208 | 0.80 | CA2 (0.33) | CA2CA4CA5AUSP2TSHR | |
| SCHEMBL7331335 | 0.76 | KMT2A (0.48) | CA2CA4TSHRALDH1A1MEN1 | |
| SCHEMBL17099130 | 0.76 | NPSR1 (0.49) | CA2TSHRGAAALDH1A1MEN1 | |
| SCHEMBL8794449 | 0.72 | MEN1 (0.49) | TSHRGAAALDH1A1MEN1KMT2A | |
| SCHEMBL362216 | 0.72 | TSHR (0.37) | CA2CA4CA5ATSHRGAA | |
| SCHEMBL13493153 | 0.67 | MAPT (0.50) | CA2CA4CA5AUSP2CFTR | |
| SCHEMBL31574395 | 0.66 | CA2 (0.58) | CA2CA4CA5AUSP2CFTR | |
| SCHEMBL14951110 | 0.65 | CA2 (0.38) | CA2CA4CA5ACFTRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4767749-A | CARDIOTONIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1988-08-30 | — | — | US | claimed |
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3682881-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-22 | — | — | EP | disclosed |
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-3110810-A1 | PYRAZOLE AMIDE DERIVATIVE | Teijin Pharma Limited (JP) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015129926-A1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-09-03 | — | — | WO | disclosed |
| CN-103596569-A | BACE-2 inhibitors for the treatment of metabolic disorders | NOVARTIS AG | 2014-02-19 | — | — | CN | disclosed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2011009943-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
| EP-0215313-B1 | EMULSION COMPOSITIONS FOR THE PARENTERAL AND/OR ORAL ADMINISTRATION OF SPARINGLY WATER SOLUBLE IONIZABLE HYDROPHOBIC DRUGS | AMERICAN CYANAMID COMPANY (US) | 1992-07-29 | — | — | EP | disclosed |
| US-5114945-A | Spiropiperidine derivatives | GLAXO GROUP LIMITED (GB) | 1992-05-19 | — | — | US | disclosed |
| US-4894368-A | CARDIOVASCULAR DISORDERS, DIURETICS | AMERICAN CYANAMID COMPANY (US) | 1990-01-16 | — | — | US | disclosed |
| EP-0330461-A2 | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1989-08-30 | — | — | EP | disclosed |
| US-4816247-A | FOR INJECTIONS | AMERICAN CYANAMID COMPANY (US) | 1989-03-28 | — | — | US | disclosed |
| US-4784845-A | FAT EMULSIONS WITH BENZYL ALCOHOL FOR DRUGS | AMERICAN CYANAMID COMPANY (US) | 1988-11-15 | — | — | US | disclosed |
| US-4767749-A | CARDIOTONIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0215313-A2 | Emulsion compositions for the parenteral and/or oral administration of sparingly water soluble ionizable hydrophobic drugs | AMERICAN CYANAMID COMPANY (US) | 1987-03-25 | — | — | EP | disclosed |
| EP-0214501-A2 | Emulsion compositions for administration of sparingly water soluble ionizable basic hydrophobic drugs | AMERICAN CYANAMID COMPANY (US) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | CA2 731/4885CA4 2492/4885CA5A 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.